Solid Biosciences Initiates SGT-003 Gene Therapy Study for Duchenne Muscular Dystrophy
Solid Biosciences has launched a multicenter, open-label study to evaluate SGT-003 in Duchenne muscular dystrophy across five age cohorts.
Asset / Drug
Drug and asset intelligence for Solid with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.